- 2024-08-20 01:54抑制剂EJMC-1|EJMC-1|397281-20-8|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 01:54抑制剂EGFR-IN-8|EGFR-IN-8|2407957-87-1|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 01:54抑制剂EGFR-IN-8|EGFR-IN-8|2407957-87-1|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 01:54抑制剂EIPA|EIPA|1154-25-2|Adamas life|≥98%（以实测数值为准）|BR|100mg
- 2024-08-20 01:54抑制剂EGFR-IN-7|EGFR-IN-7|2267329-76-8|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 01:54抑制剂EGFR-IN-7|EGFR-IN-7|2267329-76-8|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 01:54抑制剂EGFR-IN-7|EGFR-IN-7|2267329-76-8|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 01:54抑制剂EGFR-IN-8|EGFR-IN-8|2407957-87-1|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 01:54抑制剂EGFR-IN-16|EGFR-IN-16|133550-22-8|Adamas life|≥98%（以实测数值为准）|BR|100mg
- 2024-08-20 01:54抑制剂EGFR-IN-16|EGFR-IN-16|133550-22-8|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 01:54抑制剂EGFR-IN-16|EGFR-IN-16|133550-22-8|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 01:54抑制剂EAAT2 activator 1|EAAT2 activator 1|892415-28-0|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 01:54抑制剂EC330|EC330|2016795-77-8|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 01:54抑制剂EC330|EC330|2016795-77-8|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 01:54抑制剂EC330|EC330|2016795-77-8|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 01:54抑制剂E3 ligase Ligand 8|E3 ligase Ligand 8|1225383-33-4|Adamas life|≥98%（以实测数值为准）|BR|100mg
- 2024-08-20 01:54抑制剂EAAT2 activator 1|EAAT2 activator 1|892415-28-0|Adamas life|≥98%（以实测数值为准）|BR|100mg
- 2024-08-20 01:54抑制剂EAAT2 activator 1|EAAT2 activator 1|892415-28-0|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 01:54抑制剂DUPA(OtBu)-OH|DUPA(OtBu)-OH|1026987-94-9|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 01:54抑制剂DUPA(OtBu)-OH|DUPA(OtBu)-OH|1026987-94-9|Adamas life|≥98%（以实测数值为准）|BR|25mg
